HEALTHCARE TODAY
  • IN THE SPOTLIGHT
  • DIGITAL HEALTH
  • PRODUCTS & SUPPLEMENTS
  • HEALTH A - Z
  • PARENTING
  • MEN'S HEALTH
  • WOMEN
  • AGEING
  • NUTRITION
  • FITNESS
  • COMPLIMENTARY MEDICINE
  • ABOUT US
  • IN THE SPOTLIGHT
  • DIGITAL HEALTH
  • PRODUCTS & SUPPLEMENTS
  • HEALTH A - Z
  • PARENTING
  • MEN'S HEALTH
  • WOMEN
  • AGEING
  • NUTRITION
  • FITNESS
  • COMPLIMENTARY MEDICINE
  • ABOUT US
Search

ROCHE MALAYSIA LAUNCHES ALECENSA, A NEW ORAL MONOTHERAPY FOR LUNG CANCER 

FEB 27, 2019 @2.53PM
Picture
A new oral monotherapy for advanced ALK+ NSCLC. (Left to right) Dr Tho and Dr Adlinda at the official launch of Roche’s Alecensa.
Picture
Roche (Malaysia) Sdn Bhd today announced the approval of Alecensa (alectinib), a monotherapy oral treatment as a first line treatment in Malaysia, for people with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC).
 
Lung cancer is the leading cause of cancer-related deaths worldwide, and kills more people than the other three leading cancers combined (breast, prostate and colorectal)1. NSCLC is the most common type of cancer and accounts for more than 85% of lung cancers. ALK is one of the known mutations that occurs in NSCLC and is also known for its aggressive behaviour. Every year, an estimated 75,000 people are diagnosed with ALK+ NSCLC worldwide.
 
Data from the Malaysian Study on Cancer Survival (MySCan) recorded that lung cancer is the most “worrying” cancer among Malaysians. The average survival rate is only 11%, the lowest among patients suffering various types of cancer. It also occurs mostly in men, accounting for 69%, and in women, 31% (MySCan).
 
“Unlike other forms of lung cancer, ALK+ NSCLC is most commonly diagnosed in people with a light or non-smoking history. Women are also more likely to be diagnosed with this form of the disease than men and the patients also tend to be younger than most other NSCLC patients, with a median age of approximately 52,” said Dr Adlinda Alip, a Consultant Oncologist.

Alecensa
Alecensa is indicated for treatment of patients when the disease is advanced and has not been treated before or has been treated with the current standard of care. It specifically blocks the abnormal ALK protein that is responsible for the growth and spread of ALK+ NSCLC to other parts of the body and prevents the cancer from worsening.

“Drug resistance is a common occurrence for ALK+ NSCLC patients due to several reasons, including mutations in ALK. Patients develop resistance to the current standard of care (the reduction in effectiveness of a medication in treating a disease or condition), and nearly half see their tumours spread to the central nervous system (CNS) within one year of treatment. The recent clinical trials with data that point to the delay in the growth, spread and mutations of ALK+ NSCLC offers promising news to physicians and patients too,” said Dr Tho Lye Mun, a Consultant Oncologist.

A head-to-head study between Alecensa and the current standard of care (crizotinib) involving 303 people across 161 sites in 31 countries was conducted and in summary, the Phase III ALEX study showed that Alecensa, when given as initial (first-line) treatment, helped ALK+ NSCLC patients live significantly longer without their disease progressing. This is because the drug was found to effectively treat the growth of ALK+ NSCLC tumours that spread to other parts of the body including the brain and the central nervous system.
 
The data was recently presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting showed that Alecensa demonstrated sustained benefit in the reduction of the risk of disease progression or death by 57% after two years of follow-up in people living with ALK+ NSCLC11. The median PFS for people who received Alecensa more than tripled at 34.8 months.
 
Alecensa also demonstrated better efficacy where median PFS for people without CNS metastases was 34.8 months while median PFS for people with CNS metastases was 27.7 months.  In terms of its safety profile, Alecensa maintained a favourable tolerability where adverse events were found to be less frequent in the arm at 44.7%. The robust data presents that the duration of response for people who received Alecensa was 33.3 months.
 
“Roche’s goal is to transform the standard of care with the next generation inhibitors and today’s announcement offers great news for both physicians and patients living with ALK+ NSCLC. We are really excited by the clinical studies which demonstrate Alecensa's efficacy in extending patients’ lives without their cancer worsening. It has also reduced the risk of their cancer spreading to the brain. This data certainly supports the use of Alecensa as a first line treatment for people who are newly diagnosed with this form of lung cancer and as a second line treatment for those who have not benefited from the current standard of care,” shared Lance Duan, Managing Director, Roche (Malaysia) Sdn Bhd.
 
Alecensa has also been included in Roche’s Patient Assistance Program which is committed to helping eligible patients access the Roche medicines they are prescribed. Under the programme, the subsidised medications will benefit the patients in supporting their overall treatment cost. 
 
Alecensa is now approved in more than 57 countries as an initial (first-line) treatment for ALK+ advanced NSCLC, including in the United States, Europe, Japan and China.

RECOMMENDED
Picture
​Shield your eyes from harmful blue light with Brand's Lutein Essence

Picture
​Keytruda with chemotherapy to be the first line of treatment for patients with advanced lung cancer

​Tumour profiling for personalised cancer therapy
Picture
​​Tune Protect launch extreme sports plan

AIA unveils A-Plus health plan
Coca-cola rolls out Nutri Boost
Diapo-care cream for diaper rash
Repatha to reduce bad cholesterol
Pantai improves detection of eye diseases with OCT Technology
Sensodyne Rapid Relief helps ease tooth sensitivity
TOP STORIES
Picture
​Prince Court Medical Centre launch Intraoperative Radiotherapy for breast cancer treatment

Picture
​Blue Socks creates awareness on diabetic peripheral neuropathy

Picture
​PM Tun Mahathir launch MySalam scheme to aid B40s with critical illness and hospitalisation

Picture
Self-sampling HPV test to eliminate cervical cancer in Malaysia

Picture
​Survey reveals mental health and stress continue to affect organisation's bottom line
​Teacher's battle against pregnancy discrimination recognised with human rights award
15 companies win Malaysia's healthiest workplace awards
Malaysia ranks seventh in the world with highest number of dialysis treatment rate
Mimos to roll-out first clinically-tested non-invasive glucose monitor end of 2019
Sarawak General Hospital joins QVIA's network of globally qualified phase 1 oncology sites
Cardiac care for the economically challenged
HEALTH A - Z
Picture
​Are you in a physical - psychological abusive relationship?

Domestic violence can affect children even before they’re born
When mental illness is mistaken for demonic possession
Eating disorders - A mental health issue
How mental health affects your life
Schizophrenia: Living in a world that does not exist
Picture
Are you sad or depressed? How do you differentiate the two?
Picture
The psychology behind public masturbation and indecent exposure
Domestic violence and abuse - The impact on children and adolescents
Arson, animal cruelty and lack of remorse - traits of personality disorders to look out for in a person
CHILDREN
Picture
​Malaysia's butterfly children with skin as fragile as a butterfly wings
Picture
Is it bad to co-sleep with your baby?

MEN'S HEALTH
Have trouble peeing?
Picture
Does spicy food affect your prostate health?

Picture
​Cigarettes cause bladder cancer
Picture

IN THE SPOTLIGHT

HEALTH A - Z

MEN'S HEALTH

AGEING

NUTRITION

ABOUT US

PRODUCTS & SUPPLEMENTS

PARENTING

WOMEN

FITNESS

​COMPLIMENTARY MEDICINE

BM
​Copyright@ 2018 Healthcare Today. All rights reserved. The material in this site is intended to be of general information use and is not intended to constitute medical
advice, probable diagnosis or recommended treatments.                                                              
  • IN THE SPOTLIGHT
  • DIGITAL HEALTH
  • PRODUCTS & SUPPLEMENTS
  • HEALTH A - Z
  • PARENTING
  • MEN'S HEALTH
  • WOMEN
  • AGEING
  • NUTRITION
  • FITNESS
  • COMPLIMENTARY MEDICINE
  • ABOUT US